Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Atai Beckley Inc.NASDAQ: ATAI

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures turns positive

Q2 FY2026 capital expenditures was $0, compared with -$5.13M a year earlier. Trailing-twelve-month capital expenditures was -$5.46M. Over 3 fiscal years it compounded at -4.2% a year.

Context

  • Capital expenditures amounted to 22.0% of revenue in FY2025, down 8.8 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$1.37M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
-$901K+848.4% YoY
LTMJun 2026
-$5.46M-0.4% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year+848.4%——
3-year CAGR-4.2%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(901K) USD
Year-over-year change
-848.4%

Capital Expenditures vs competitors

How ATAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.4% is the 5th highest of 10, against a peer median of -58.3%.
  • Capital expenditures amounts to 122.2% of revenue for ATAI, versus a peer median of 0.6%.
ATAI Competitors
Capital Expenditures for ATAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATAIAtai Beckley Inc.LTM Jun 2026$5.46M USD-0.4%-4.2%122.2%
IMTXImmatics N.V.LTM Mar 2026€4.36M EUR-58.3%+0.4%11.7%
SANASana Biotechnology, Inc.LTM Mar 2026$1.09M USD-93.8%-64.4%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$487K USD-64.1%-30.0%—
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$334K USD+165.1%+15.3%17.5%
NKTRNektar TherapeuticsLTM Jun 2026$262K USD-77.5%-68.9%0.5%
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$193K USD+22.2%-36.3%—
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$187K USD—-6.0%0.1%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$141K USD+95.8%-62.1%—
INBXInhibrx Biosciences, Inc.LTM Mar 2026$10K USD-99.3%-64.4%0.8%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$0 USD+100.0%-64.4%0.0%
Peer median (excluding ATAI) —-58.3%-49.2%0.6%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(174.24M)(157.42M)(43.9M)(150.05M)(660.05M)
Depreciation & Amortization47K168K319K473K1.01M
Deferred Income Tax39.14M5.07M000
Stock-Based Compensation63.36M42.38M32.98M25.49M0
Change in Working Capital(7.6M)(3.34M)7.47M(9.2M)(6.48M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.3M(3.03M)2.14M(1.87M)(1.7M)
Other Working Capital(9.9M)(301K)5.33M(7.33M)(4.78M)
Other Non-Cash Items16.06M8.67M(80.99M)50.85M562.84M
Operating Cash Flow(63.25M)(104.47M)(84.12M)(82.44M)(102.68M)
Capital Expenditures(1.13M)(1.02M)(590K)(95K)(901K)
Acquisitions (Net)(52.94M)0(443K)359K4.64M
Purchases of Investments(23.66M)(309.66M)(186.22M)(15M)(98.95M)
Sales of Investments(955K)226.83M139.47M82.01M9.05M
Other Investing Activities(2.6M)(3.25M)(5.84M)(8.1M)(13M)
Investing Cash Flow(81.28M)(86.85M)(53.3M)59.17M(109.13M)
Debt Repayment1.59M15M05M7.71M
Common Stock Issued409.88M00535K283.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.42M5.19M(8.36M)(161K)(21.66M)
Financing Cash Flow409.86M20.79M(8.36M)5.37M269.48M
Effect of Forex Changes(320K)(1.12M)189K362K116K
Net Change in Cash265.02M(171.65M)(145.58M)(17.53M)57.8M
Free Cash Flow(64.37M)(105.49M)(84.71M)(82.53M)(103.58M)

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.